Andere Kunden interessierten sich auch für
![Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions]( "Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions")
Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions88,99 €![Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions]( "Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions")
Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions74,99 €![Monitoring for Adverse Drug Reactions]( "Monitoring for Adverse Drug Reactions")
Monitoring for Adverse Drug Reactions166,99 €![Pharmacovigilance and Adverse Drug Reactions reporting:]( "Pharmacovigilance and Adverse Drug Reactions reporting:")
Pharmacovigilance and Adverse Drug Reactions reporting:23,99 €![Adverse Drug Reactions Reporting by Consumers in Penang-Malaysia]( "Adverse Drug Reactions Reporting by Consumers in Penang-Malaysia")
Adverse Drug Reactions Reporting by Consumers in Penang-Malaysia48,99 €![Adverse drug reactions caused by HAART at clinics in Lesotho]( "Adverse drug reactions caused by HAART at clinics in Lesotho")
Adverse drug reactions caused by HAART at clinics in Lesotho42,99 €![Assessment of Adverse Drug Reactions in Respiratory Disease Patients]( "Assessment of Adverse Drug Reactions in Respiratory Disease Patients")
Assessment of Adverse Drug Reactions in Respiratory Disease Patients32,99 €
The aim of our study is to assess the incidence of Cutaneous Adverse Drug Reactions in the in-patient and out-patient wings of the dermatology department in the tertiary care hospitals. From the study it was concluded that Fixed Drug eruptions are the most frequently observed Cutaneous Adverse Drug Reactions followed by maculopapular rash. We identified that the most common drugs responsible are NSAIDs followed by Anti epileptics. Depending upon nature of ADR, the dermatological ADR varied in their appearance, duration, causality, severity. To minimize the incidence of CADRs the healthcare system should promote the spontaneous reporting of dermatological adverse reactions to pharmacovigilance centers.